Abstracts tagged "MALT lymphoma and salivary gland"

Abstract Number: 2435 • 2019 ACR/ARP Annual Meeting
Data Driven Prediction Lymphoma Model and 10-year Overall Survival Rates of a Large Harmonized Cohort of Patients with Primary Sjögren’s Syndrome Associated Lymphomas
Andreas Goules ¹, Michael Voulgarelis ², Loukas Chatzis², Vasilis Pezoulas ³, Francesco Ferro ⁴, Saviana Gandolfo ⁵, Valentina Donati ⁶, Luca Quartuccio ⁷, Cathryn Scott ⁸, Ginevra De Marchi ⁹, Georgios Michalopoulos ¹, Aliki Venetsanopoulou ¹, Aristea Papageorgiou ¹, Dimitris Ziogas ¹, Marina Sikara ¹, Argyropoulou Ourania ¹, Clio Mavragani ¹, Dimitris fotiadis ¹⁰, Salvatore De Vita ⁵, Chiara Baldini ⁴ and Athanasios Tzioufas ², ¹Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, athens, Greece, ²Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ³Unit of Medical Technology and Intelligent Information Systems, University of Ioannina, GR45110, Ioannina, Greece, Ioannina, Greece, ⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ⁵Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ⁶University of Pisa, Pisa, ⁷Rheumatology Clinic, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ⁸Institute of Anatomic Pathology, Department of Medical Area, University of Udine, Udine, Italy. *equally contributed, Udine, Italy, ⁹Rheumatology Clinic, Udine University Hospital, Udine, Italy, Udine, Italy, ¹⁰Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Ioannina, Greece
Background/Purpose: Non-Hodgkin’s lymphomas (NHLs) may complicate primary Sjögren’s syndrome (pSS) with significant impact on morbidity and mortality among patients. A large cohort of SS associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].